Binnopharm Group announces an appointment of a new CEO

The international pharmaceutical company Binnopharm Group announces an appointment of Andrey Potapov as a CEO. In his new role, he will be responsible for strategic business development, strengthening the company’s market position and implementing long-term growth initiatives.

Andrey Potapov has over 20 years of experience in the pharmaceutical industry and financial management. He graduated from the Novosibirsk State University with a degree in Economic Cybernetics and received additional economic education in the United States.

In 2023, he became the head of Stentex, having previously managed Takeda’s business in Russia and following regions: CIS, Middle East, Africa, Turkey, India.

Andrey Potapov’s appointment opens up a new stage in the development of Binnopharm Group. His management experience, deep expertise in the pharmaceutical industry, and multiple years of work in international markets will contribute to further business strengthening and implementation of the company’s strategic objectives.

Rustem Muratov, who headed Binnopharm Group since 2020, is leaving the company. Under his leadership, Binnopharm Group achieved significant results: it became one of the fastest-growing pharmaceutical companies in Russia, ranked sixth in the Russian retail market, ranked first among Russian companies in export to neighbouring markets, and actively implemented an international expansion strategy, opening a subsidiary in China and a representative office in Vietnam.